Bolton (MA), San Antonio (TX) (PRWEB) June 04, 2016 -- Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified imaging core lab, announced today that it has been awarded a global Phase III clinical trial designed to investigate the safety and efficacy of a novel approach to treat Non-Small Cell Lung Cancer Brain Metastases.
With its team of over 65 full time board certified, fellowship trained radiologists, Intrinsic Imaging has extensive experience in providing services in support of Phase I-IV Clinical Trials and Class I, II and III Medical Device Trials.
Throughout this multi-year trial, which includes several thousand radiological reads, Intrinsic Imaging oncology team of 10 full-time radiologists and 9 full-time neuroradiologists will bring their wealth of expertise and experience and provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer and quality control, radiological review and data management.
“Intrinsic Imaging is proud to be selected to provide our expertise in assessing if this treatment will be effective to treat non-small cell lung cancer brain metastases,” said Todd A. Joron, President & COO at Intrinsic Imaging. “The results of this Phase III study will determine if this novel approach compares favorably to the efficacy and safety of standard of care for this indication.”
Intrinsic Imaging’s breath of experience in oncology related studies includes the qualitative and quantitative imaging evaluation of cancers of multiple cell types including carcinomas, sarcomas, myeloma as well as leukemia and lymphomas. Intrinsic Imaging also has significant expertise in assessment criteria including, but not limited to, RECIST, PERCIST, Cheson, irRECIST, RANO and Macdonald.
According to global cancer statistics, Lung cancer is the leading cause of cancer mortality worldwide, accounting for approximately 1.38 million annual deaths. Among those, around 7.4% of non-small cell lung cancer (NSCLC) patients will have brain metastases at presentation and another 25–30% will develop brain metastases over the course of their disease. Life-expectancy for these patients is limited, with a median survival of only 3.4 months. Moreover, many will suffer considerable loss of autonomy due to neurocognitive and functional deficits.
About Intrinsic Imaging
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, 13485 and 22301 certified, medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than sixty-five board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world.
For more information on this release or Intrinsic Imaging, please contact Craig Pennington at craig.pennington(at)intrinsicimaging.com or visit our website at http://www.intrinsiccro.com.
Craig Pennington, Intrinsic Imaging LLC, http://www.IntrinsicCRO.com, +1 (978) 798-2400, [email protected]
Share this article